WO2004047727A3 - Compositions and methods for diagnosing and treating mood disorders - Google Patents

Compositions and methods for diagnosing and treating mood disorders Download PDF

Info

Publication number
WO2004047727A3
WO2004047727A3 PCT/US2003/035066 US0335066W WO2004047727A3 WO 2004047727 A3 WO2004047727 A3 WO 2004047727A3 US 0335066 W US0335066 W US 0335066W WO 2004047727 A3 WO2004047727 A3 WO 2004047727A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
compositions
mood disorders
treating mood
Prior art date
Application number
PCT/US2003/035066
Other languages
French (fr)
Other versions
WO2004047727A2 (en
Inventor
Huda Akil
Jr William E Bunney
Prabhakara V Choudary
Simon J Evans
Edward G Jones
Jun Li
Juan F Lopez
Robert C Thompson
Richard Myers
Hiroaki Tomita
Marquis P Vawter
Stanley Watson
Original Assignee
Univ Leland Stanford Junior
Huda Akil
Jr William E Bunney
Prabhakara V Choudary
Simon J Evans
Edward G Jones
Jun Li
Juan F Lopez
Robert C Thompson
Richard Myers
Hiroaki Tomita
Marquis P Vawter
Stanley Watson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Huda Akil, Jr William E Bunney, Prabhakara V Choudary, Simon J Evans, Edward G Jones, Jun Li, Juan F Lopez, Robert C Thompson, Richard Myers, Hiroaki Tomita, Marquis P Vawter, Stanley Watson filed Critical Univ Leland Stanford Junior
Priority to AU2003291720A priority Critical patent/AU2003291720A1/en
Priority to EP03768612A priority patent/EP1573039A4/en
Priority to CA002503246A priority patent/CA2503246A1/en
Publication of WO2004047727A2 publication Critical patent/WO2004047727A2/en
Publication of WO2004047727A3 publication Critical patent/WO2004047727A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods for diagnosing mental disorders such as mood disorders, including bipolar disorder I and II and major depression. The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.
PCT/US2003/035066 2002-11-01 2003-11-03 Compositions and methods for diagnosing and treating mood disorders WO2004047727A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003291720A AU2003291720A1 (en) 2002-11-01 2003-11-03 Compositions and methods for diagnosing and treating mood disorders
EP03768612A EP1573039A4 (en) 2002-11-01 2003-11-03 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MOOD DISORDERS
CA002503246A CA2503246A1 (en) 2002-11-01 2003-11-03 Compositions and methods for diagnosing and treating mood disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42324702P 2002-11-01 2002-11-01
US60/423,247 2002-11-01
US43145402P 2002-12-06 2002-12-06
US60/431,454 2002-12-06

Publications (2)

Publication Number Publication Date
WO2004047727A2 WO2004047727A2 (en) 2004-06-10
WO2004047727A3 true WO2004047727A3 (en) 2005-05-06

Family

ID=32397053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035066 WO2004047727A2 (en) 2002-11-01 2003-11-03 Compositions and methods for diagnosing and treating mood disorders

Country Status (5)

Country Link
US (2) US7410759B2 (en)
EP (1) EP1573039A4 (en)
AU (1) AU2003291720A1 (en)
CA (1) CA2503246A1 (en)
WO (1) WO2004047727A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1573039A4 (en) * 2002-11-01 2008-04-16 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MOOD DISORDERS
AU2011211453B2 (en) * 2004-06-21 2015-01-15 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
DK1766077T3 (en) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentially expressed genes and pathways in bipolar disorder and / or severe depressive disorder
CA2629299C (en) 2005-11-12 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
GB0616230D0 (en) * 2006-08-16 2006-09-27 Univ Cambridge Tech Biomarkers and uses thereof
GB0808832D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808834D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808833D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB201204816D0 (en) 2012-03-19 2012-05-02 Brainco Biopharma S L Transgenic animal model of mood disorders
CN108508211B (en) * 2018-04-04 2021-05-04 中央民族大学 Serum marker FGF9 in first-episode drug-naive patients with schizophrenia and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
US20040152107A1 (en) * 2002-09-18 2004-08-05 C. Anthony Altar Gene signature of electroshock therapy and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
FR2718150B1 (en) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
CA2216686A1 (en) 1997-09-24 1999-03-24 Guy A. Rouleau Allelic variants of the phospholipase c-gamma1 gene associated with bipolar disorder
BR9911068A (en) * 1998-05-29 2001-02-06 Lilly Co Eli Combination therapy for the treatment of bipolar disorders
AUPP810399A0 (en) 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
EP1165836A2 (en) * 1999-03-30 2002-01-02 Genset Schizophrenia associated genes, proteins and biallelic markers
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
EP1410036A2 (en) 2001-01-19 2004-04-21 Mindsense Biosystems Ltd. Methods and compositions for diagnosing and treating a subject having depression
EP1233075A3 (en) 2001-02-15 2003-01-08 Whitehead Institute For Biomedical Research BDNF polymorphism and association with bipolar disorder
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US20030152972A1 (en) * 2001-11-08 2003-08-14 Whitehead Institute For Biomedical Research Gene expression associated with psychiatric disorders
US6787135B2 (en) * 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
EP1573039A4 (en) * 2002-11-01 2008-04-16 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MOOD DISORDERS
DK1766077T3 (en) * 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentially expressed genes and pathways in bipolar disorder and / or severe depressive disorder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
US20040152107A1 (en) * 2002-09-18 2004-08-05 C. Anthony Altar Gene signature of electroshock therapy and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRIMES C.A. ET AL.: "Cholinergic stimulation of early growth response-1 DNA bingind activity requires protein kinase C and mitogen-activated protein kinase kinase activation and is inhibited by sodium valporate in SH-SY5Y cells", JOURNAL OF NEUROCHEMISTRY, vol. 73, no. 4, October 1999 (1999-10-01), pages 1384 - 1392 *
HERDEGEN T. ET AL.: "JUN, FOS, KROX, and CREB transcription factor proteins in the rat cortex: basal expression and induction by spreading depression and apileptic seitures", THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 333, no. 2, pages 271 - 288 *
SABBAN E.L. ET AL.: "Differential effects of gene transcription factors in catecholaminergic systems", ANN. N.Y. ACAD. SCI. USA, vol. 1032, December 2004 (2004-12-01), pages 130 - 140 *
See also references of EP1573039A4 *

Also Published As

Publication number Publication date
WO2004047727A2 (en) 2004-06-10
EP1573039A4 (en) 2008-04-16
US7410759B2 (en) 2008-08-12
US20090117565A1 (en) 2009-05-07
EP1573039A2 (en) 2005-09-14
US20040152111A1 (en) 2004-08-05
AU2003291720A1 (en) 2004-06-18
CA2503246A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
EP2453024A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MXPA04006280A (en) Spiroazacyclic compounds as monoamine receptor modulators.
CY1112238T1 (en) ANTI-KINESIN SUSPENSIONS AND METHODS OF USING THESE
EP1990338A3 (en) Biphenylcyclopropylamides as p-38 Kinase inhibitors
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ATE259215T1 (en) COMPOSITION FOR REGULATING SKIN APPEARANCE
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
ATE540129T1 (en) TARGET FOR THE THERAPY OF COGNITIVE DISABILITIES
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005081619A3 (en) Compounds and methods for increasing neurogenesis
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
WO2007005940A3 (en) Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2003106656A3 (en) Single domain tdf-related compounds and analogs thereof
ATE494903T1 (en) USE OF SLURP-1 TO TREAT DISEASES CAUSED BY ACETYLCHOLINE RECEPTOR DISRUPTIONS
AU2003211040A8 (en) The eaat2 promoter and uses thereof
WO2006078776A3 (en) Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
WO2003106972A3 (en) Multiple domain tdf-related compounds and analogs thereof
TW200505435A (en) Treatment of ocular disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003291720

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2503246

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003768612

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003768612

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

OSZAR »